caprotec bioanalytics and Merck KGaA Sign Collaboration Agreement

30-May-2008

caprotec bioanalytics GmbH announced that they have signed a collaboration agreement with Merck KGaA acting for its division Merck Serono. Under the terms of the agreement caprotec will apply its Capture Compound Mass Spectrometry(TM) (CCMS) Technology to identify relevant protein - drug molecule interactions for one of Merck Serono's research projects. caprotec will receive research funding and potential milestone payments on product development. Further financial details of the agreement were not disclosed.

"The collaboration with Merck Serono is an important milestone for caprotec. Merck Serono is a leader and innovator in the field, and this collaboration validates our capabilities for the development of improved small molecules." says caprotec's COO Mathias Grote. "Being able to collaborate with such an established player in this field provides an important further endorsement of our technology in the pharmaceutical industry".

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic World Mass Spectrometry

Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

4 products
4 brochures
View topic world

Topic World Mass Spectrometry

Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

4 products
4 brochures